European Regulators To Review Elan's and Biogen's Tysabri

European regulators will review the multiple sclerosis drug Tysabri made by Elan (NYSE: ELN) and Biogen (Nasdaq: BIIB) after 23 reported cases of the brain infection progressive multifocal leukoencephalopathy. Shares of Elan tumbled $1.14 to $5.30 while Biogen stock dropped $2.47 to $44.76.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.